OpenNashEarnings

Health Insurance · NYSE: CI

Cigna Group earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 4 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Cigna launched Health Sense, advanced its fee-based Signature pharmacy model toward a January 2027 start, and reported a strong 2027 selling season with 250+ new pharmacy clients.

Cigna launched Health Sense, a customer support model that starts with oncology and connects medical, pharmacy and benefit information so clinical teams can step in earlier. Specialty pharmacy kept gaining from lower-cost biosimilars and generics, with generic Revlimid adoption near 90%, while the pharmacy benefit business absorbed large client renewals. Employer demand held up: medical customers grew 2%, led by small-business Select clients, and the 2027 pharmacy selling season is tracking strong.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗

Quarters

KPI history

Revenue$73.7B+5.6% y/yQ3 2026
Q4 2024: $65.6B (worked out from the annual figure)Q4 ’24$65.6BQ1 2025: $65.5BQ1 ’25$65.5BQ2 2025: $67.2BQ2 ’25$67.2BQ3 2025: $69.7BQ3 ’25$69.7BQ4 2025: $72.5B (worked out from the annual figure)Q4 ’25$72.5BQ1 2026: $68.5BQ1 ’26$68.5BQ2 2026: $71.7BQ2 ’26$71.7BQ3 2026: $73.7BQ3 ’26$73.7B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$65.6B *
Q1 2025$65.5B
Q2 2025$67.2B
Q3 2025$69.7B
Q4 2025$72.5B *
Q1 2026$68.5B
Q2 2026$71.7B
Q3 2026$73.7B
Diluted EPS (GAAP)$5.47−21.6% y/yQ3 2026
Q1 2025: $4.85Q1 ’25$4.85Q2 2025: $5.71Q2 ’25$5.71Q3 2025: $6.98Q3 ’25$6.98Q1 2026: $6.26Q1 ’26$6.26Q2 2026: $6.29Q2 ’26$6.29Q3 2026: $5.47Q3 ’26$5.47
Data
Q1 2025$4.85
Q2 2025$5.71
Q3 2025$6.98
Q1 2026$6.26
Q2 2026$6.29
Q3 2026$5.47

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin3.3%−0.4 pts y/yQ3 2026
Q4 2024: 3.3%Q4 ’243.3%Q1 2025: 3.0%Q1 ’253.0%Q2 2025: 3.4%Q2 ’253.4%Q3 2025: 3.7%Q3 ’253.7%Q4 2025: 3.2%Q4 ’253.2%Q1 2026: 3.4%Q1 ’263.4%Q2 2026: 3.7%Q2 ’263.7%Q3 2026: 3.3%Q3 ’263.3%
Data
Q4 20243.3%
Q1 20253.0%
Q2 20253.4%
Q3 20253.7%
Q4 20253.2%
Q1 20263.4%
Q2 20263.7%
Q3 20263.3%
Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$65.6Bd$65.5B$67.2B$69.7B$72.5Bd$68.5B$71.7B$73.7B
Operating income$2.2Bd$2.0B$2.3B$2.6B$2.3Bd$2.4B$2.7B$2.4B
Operating margin3.3%3.0%3.4%3.7%3.2%3.4%3.7%3.3%
Net income$1.5Bd$1.3B$1.5B$1.9B$1.2Bd$1.7B$1.7B$1.4B
Diluted EPS—$4.85$5.71$6.98—$6.26$6.29$5.47
Operating cash flow$5.2Bd$1.9B-$1.9Bd$3.4Bd$6.1Bd$1.1B-$421.0Md$2.6Bd

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings